Eli Lilly and Co at Citi BioPharma Conference Transcript

Sep 07, 2022 / 07:30PM GMT
Andrew Simon Baum - Citigroup Inc., Research Division - Global Head of Healthcare Research and MD

So good afternoon. Welcome back. Delighted to introduce our session. We have from Lilly, Dan Skovronsky, the CSO, CMO and President of Lilly R&D. Did I get that right?

Daniel M. Skovronsky - Eli Lilly and Company - Senior VP, Chief Scientific & Medical Officer and President of Lilly Research Labs

Yes, perfect.

Andrew Simon Baum - Citigroup Inc., Research Division - Global Head of Healthcare Research and MD

All 3, excellent. I'm doing well. So we have about 40 minutes. I'd like to make this session interactive. Lilly currently enjoys by far the highest multiple of the group, which I'm sure everyone in this room knows.

Questions and Answers:

Andrew Simon Baum - Citigroup Inc., Research Division - Global Head of Healthcare Research and MD

Maybe just to kick off on donanemab, which is a program. We obviously have lecanemab data upcoming. We have the data from
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot